All In Biotech

Drug Trial Radar · NCT06866613

Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.

Randomized, Controlled, Double-blind, Multi-center Trial to Evaluate the Efficacy and Safety of an Esflurbiprofen Topical System (EFTS) vs. Placebo in the Local Symptomatic and Short-term Treatment of Pain in Ankle Sprains.

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

70

Actual

Start

Mar 31, 2025

Primary completion

Oct 18, 2025

Study completion Oct 30, 2025

Sponsor

Lead sponsor
Teikoku Seiyaku Co., Ltd.Industry
Sponsor type
Industry
Collaborators
CRM Biometrics GmbH; SocraTec R&D GmbH; SocraMetrics GmbH; HWI pharma services GmbH; Clinsearch GmbH
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, double-blind, randomized controlled trial to evaluate the efficacy and safety of EFTS vs. placebo in patients with ankle sprains. The primary objective of this study is to demonstrate that the EFTS is superior in pain reduction compared to a matching placebo in patients with ankle sprains. The secondary objective is to evaluate tolerability, local tolerability, and adhesion of EFTS vs. placebo.

Conditions

  • Ankle Sprains

Interventions

  • Esflurbiprofen Topical System (EFTS)Drug

    One EFTS is applied to the injured area over consecutive 7 days

  • Placebo PatchDrug

    One placebo patch is applied to the injured area over consecutive 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sum of Pain Intensity Difference (SPID) on Pain-on-movement (POM) Over 0-48 HoursTime frame: Day 1 to Day 3

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Medical Practice Ebert

    Siemensstr, Bonn, Germany

  • Medical Practice Prof. Predel

    Siemensstr, Bonn, Germany

  • Medical Practice Schaale-Maas

    Siemensstr, Bonn, Germany

  • Medical Practice Pabst

    Sportschule Puch, Fürstenfeldbruck, Germany

  • Medical Practice Gastl

    Römerstraße, Gilching, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.